ClinicalTrials.gg
CompletedNCT03482128SONALGUpdated May 18, 2018

Blood Transfusion and Postoperative Outcome Before and After Implementing a Coagulation Management Algorithm

An observational study in Coagulation Disorder, Blood, sponsored by Triemli Hospital. Completed at 1 site in Switzerland. Per ClinicalTrials.gov, last updated 2018-05-18.

Sponsored by Triemli Hospital · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,754
Sex
All
01

Study summary

Implementing coagulation management algorithms based on Point-of-care (POC) testing devices such as thromboelastography (TEG) or rotational thromboelastometry (ROTEM) have been shown to reduce transfusion rates and the occurrence of adverse patient outcomes. Apart from the TEG and ROTEM, another viscoelastic POC measurement technique, the SONOCLOT, can be easily used at the bedsite. However Information regarding a SONOCLOT based coagulation management algorithm however is lacking.

Transfusion rates of allogeneic blood products (Red blood cells = RBC, Fresh frozen plasma = FFP, Platelet concentrates = PLT) and patient adverse outcomes in two cohorts before and after the implementation of a SONOCLOT based coagulation management algorithm were evaluated on an observational basis in 1754 patients undergoing different types of cardiac surgery. The effect of the cohort and 19 predictors on transfusion was assessed by relative R2-values obtained by bootstrapping and a hurdle regression model, comprising a binomial and a Poisson count component. Association of predictors with post-operative outcomes was assessed with a logistic regression model.

Read the detailed description

Patient data and all relevant procedure related data of cardiac surgery procedures at the Triemli City Hospital, Switzerland are recorded in a dedicated database with the approval of the institutional research ethics board and patient informed consent. Data analysis focusing on coagulation management using a dedicated algorithm in the present quality control study is done for 1754 out of 2199 consecutive patients undergoing cardiac surgery comprising the initial cohort from 2009 to 2011 (before implementation of the algorithm) and the subsequent cohort from 2013 to 2015 (after implementation of the algorithm).

In the time period analyzed for this study anesthesia and intensive care were performed according to standardized protocols. Fluid management was done with lactated Ringer's solution and synthetic colloids. Different blood conservation strategies were used and included consistently cell salvage, standardized application of tranexamic acid and retrograde autologous cardiopulmonary bypass (CPB) priming. Anticoagulant medication was suspended at least 5 days prior to surgery for all elective procedures. Hematocrit measurements were performed using a standard POC blood gas analyzer available in the OR. Indication for red blood cells (RBC) transfusion were a hematocrit (HCT) level below 21% during CPB, below 25% for patients with preserved left ventricular function and 28% for patients with a left ventricular function ≤ 30% and patients undergoing emergency procedures. Standard laboratory tests (blood count, international normalized ratio (INR) / prothrombin time (PT), activated partial thromboplastin time (aPTT) fibrinogen concentration (FIB) were routinely available for guiding transfusion of coagulation blood products. Coagulation management before the implementation of the algorithm was performed based on institutional guidelines in accordance with published recommendations. Kaolin activated clotting time (ACT) measurements were used to guide heparin and protamine management. After heparin reversal and ongoing bleeding prothrombin complex concentrate was applied at a PT ≤ 70% / INR threshold of 1.5 and in selected cases with ongoing major bleeding fresh frozen plasma (FFP) was used to normalize PT/INR. Moreover, fibrinogen concentrate was given below a fibrinogen level of 1 g/l. Platelet concentrates (PLT) were transfused when platelet count was ≤ 100 x 109/lit. PLT were also given in suspected platelet dysfunction. When severe bleeding occurred at the end of the surgical procedure coagulation management was started on an empirical basis by the anesthesiologist in charge.

The SONOCLOT coagulation management algorithm is based on existing literature on this subject and the experience of the authors with the specific POC technique: It considers standard coagulation lab results and platelet function tests and includes the use of the MULTIPLATE analyzer. SONOCLOT measurements consist basically of three dedicated tests:

  1. A kaolin ACT that is being applied for heparin and protamine administration.
  2. A glass-bead ACT providing information about the initiation of the clotting process, the propagation of the coagulation and platelet function.
  3. A glass-bead ACT with heparinase in case the measurement has to be performed under heparin.

First coagulation measurements in each patient undergoing cardiac surgery are executed in the pre-intervention period. The established baseline values trigger the preparation of coagulation blood products that will be applied in the post-interventional period. At the end of the surgical procedure, heparin reversal is performed according to the Bulls protocol. After initial antagonisation with protamine kaolin ACT and glass-bead ACT as well as a heparinase glass-bead ACT are done to primarily detect any residual heparin. For any registered serum heparin the treatment and measurement loop is repeated. In case of an ongoing bleeding after heparin reversal a surgery-related cause has to be excluded and then another treatment and management loop based on glass-bead ACT is initiated and repeated until coagulation has been restored. As soon as results of the standard lab test are available in the postoperative period these are included in the decision making process.

Primary outcome parameters were transfusion rates during the operation and the treatment in the ICU. Secondary outcome parameters included morbidity: an mortality in the postoperative period during the hospital stay.

Statistical analysis will be performed with the software package R. To compare patient-related demographic and perioperative data prior and post algorithm implementation and univariable analysis are performed. Based on the data format and distribution, either Fisher's exact test, t-tests or Wilcoxon rank sum test were applied. For the assessment of the difference of transfusion in the two cohorts and controlling potential influence of other factors two approaches have been chosen. First, after a continuity-corrected log-transformation of the units of RBC given, a sequence of preoperative and procedure related predictors were included in the analysis. To check for multi-colinearity, variance inflation factors are assessed with the R package. Furthermore, to assess the association between potential risk factors and the incidence of postoperative infections a generalized linear model with a binomial link and logit function was chosen and performed with the R package.

02

Conditions studied

  • Coagulation Disorder, Blood

Keywords

  • transfusion
  • coagulation
  • cardiac surgery
03

In context

Blood Coagulation Disorders

147 studies on the registry are indexed under Blood Coagulation Disorders; 15 are open to participants now.

This study's enrollment of 1,754 is above the median of 120 across 58 observational studies indexed under Blood Coagulation Disorders.

Browse Blood Coagulation Disorders studies →

Lead sponsor

Triemli Hospital is the lead sponsor of 12 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients undergoing cardiac surgery at the Triemli City Hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing cardiac surgery at the Triemli City Hospital
  • Coronary artery bypass grafting
  • Valve intervention (Aortic/Mitral/Tricuspid)
  • Aortic surgery
  • Time period before implementation of a coagulation management guided by SONOCLOT
  • Time period after implementation of a coagulation management guided by SONOCLOT

Exclusion criteria

Exclusion

  • Time period during implementation of a coagulation management guided by SONOCLOT
  • Missing data in data base
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,754 participants (actual)
Patient registry
No

Groups and cohorts

  • preAlgorithm

    Standard coagulation management of patients undergoing cardiac surgery

    Device: Standard coagulation management

  • postAlgorithm

    Coagulation management guided by SONOCLOT of patients undergoing cardiac surgery

    Device: Coagulation management guided by SONOCLOT

Interventions

  • DeviceCoagulation management guided by SONOCLOT

    Application of blood products guided by SONOCLOT measurements

  • DeviceStandard coagulation management

    Application of blood products based on clinical experience of the anesthesiologist in charge

06

What researchers measure

Primary outcomes

  1. Transfusion requirement

    RBC-Red Blood Cells (units), FFP-Fresh Frozen Plasma (units), PLT-Platelets (units)

    Time frame: Postoperative hospital stay; on average 8 days

Secondary outcomes

  1. Postoperative complications

    Infections, myocardial infarction, cerebrovascular insult, acute renal failure

    Time frame: Postoperative hospital stay; on average 8 days

  2. Mortality

    Death

    Time frame: Postoperative hospital stay; on average 8 days

07

Study locations

1 site
  • Triemli City Hospital
    Zurich, 8063, Switzerland
08

References and documents

Publications

  • Serraino GF, Murphy GJ. Routine use of viscoelastic blood tests for diagnosis and treatment of coagulopathic bleeding in cardiac surgery: updated systematic review and meta-analysis. Br J Anaesth. 2017 Jun 1;118(6):823-833. doi: 10.1093/bja/aex100. PubMed 28475665 ↗
  • Deppe AC, Weber C, Zimmermann J, Kuhn EW, Slottosch I, Liakopoulos OJ, Choi YH, Wahlers T. Point-of-care thromboelastography/thromboelastometry-based coagulation management in cardiac surgery: a meta-analysis of 8332 patients. J Surg Res. 2016 Jun 15;203(2):424-33. doi: 10.1016/j.jss.2016.03.008. Epub 2016 Mar 26. PubMed 27363652 ↗
  • Whiting P, Al M, Westwood M, Ramos IC, Ryder S, Armstrong N, Misso K, Ross J, Severens J, Kleijnen J. Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2015 Jul;19(58):1-228, v-vi. doi: 10.3310/hta19580. PubMed 26215747 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2011 to primary completion in Dec 2015, 59 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2018
First posted
Mar 29, 2018
StartActual
Jan 1, 2011
Primary completionActual
Dec 31, 2015
CompletionActual
Dec 31, 2015
Last update
May 18, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03482128
Lead sponsor
Triemli Hospital
Responsible party
Christoph K Hofer (Prof. Dr. med, Triemli Hospital) — Principal investigator
First posted
Mar 29, 2018
Start date
Jan 1, 2011
Primary completion
Dec 31, 2015
Completion
Dec 31, 2015
Last update
May 18, 2018

Study contacts

Michele Genoni, MD, Prof
study chair · Triemli City Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion